Seeing the wood from the trees

The annual AACR meetings are where we look for hidden gems, new trends, novel targets, as well as a raft of early stage agents coming out of company pipelines.

The problem is which ones stand out from the crowd and how do we attempt to see the solid wood from the mass of trees surrounding us?  Unfortunately, it isn’t always obvious and the first past the initial stage of development isn’t necessarily the best example or most optimised in the long run.

Let’s not also forget how a whole niche can also wither overnight based on the first company’s negative results, which can be in the form of lack of efficacy – Incyte’s IDO inhibitor was a good example causing a major sneeze – or severe toxicities viz BET/Bromodomains, which fizzled out almost overnight after a promising start and a long list of competitors vying for time, space, and attention gradually faded from view.

In our latest Preview, we take a look at four early stage new developments and highlight some potential opportunities and challenges to be addressed…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by